China Three Gorges University, Yichang, China
5
1
1
3
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 65/100
20.0%
1 terminated/withdrawn out of 5 trials
75.0%
-11.5% vs industry average
20%
1 trials in Phase 3/4
0%
0 of 3 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (5)
Safety and Efficacy of Telitacicept in the Treatment of Systemic Lupus Erythematosus (SLE)
Role: collaborator
A Trial of Endostar in Combination With Chemotherapy of DF and Sequential Intensity Modulated Radiation Therapy for Patients With Advanced Nasopharyngeal Carcinoma
Role: lead
Study of Qiliqiangxin Capsule to Treat Dilated Cardiomyopathy
Role: collaborator
Effect of Age on the Median Effective Concentration(EC50) for Motor Block With Spinal Plain Bupivacaine
Role: lead
Effect of Age on the Median Effective Dose(ED50) for Motor Block With Intrathecal Ropivacaine
Role: lead
All 5 trials loaded